Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Raghda R. Ibrahim
Observed names:
Ibrahim, Raghda R.,
Raghda Ibrahim
Institutions:
Wallenberg Centre for Molecular and Translational Medicine,
University of Gothenburg
Observed institutions:
Beni-Suef University,
Mansoura University,
Wallenberg Centre for Molecular and Translational Medicine,
University of Gothenburg
ORCID:
0000-0001-7641-3141
Observed ORCID:
0000-0001-7641-3141
OpenAlex ID:
A5086308164
Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
·
Cancer Research Communications
·
16
Personalized circulating tumor DNA analysis for sensitive disease monitoring and detection of relapse in neuroblastoma
2024
·
Ida Rahmqvist
, Enya Engström
, et al.
·
Biomarker Research
·
6
PDF
Patient-specific sequencing panels enable sensitive circulating tumor DNA analysis in rhabdomyosarcoma independent of genetic profile
2025
·
Ida Rahmqvist
, Agnes Dahlstrand Rudin
, et al.
·
npj Precision Oncology
·
3
PDF
Evaluation of the adenosine deaminase (ADA) G22A gene polymorphism with recurrent spontaneous abortion among Egyptian patients
2017
·
Hanan Mohamed Farhan
, Khadiga Abu-Gabal
, et al.
·
Central European Journal of Immunology
·
3
PDF
Supplementary information from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
·
1
The Effect of Unique Molecular Identifier Family Size Using Tumor-Informed Circulating Tumor DNA Analysis in Childhood Cancers
2026
·
Tobias Österlund
, Daniel Andersson
, et al.
·
Journal of Molecular Diagnostics
PDF
Harmonization of Reporting for Detection of ALK Genetic Alterations in Neuroblastoma: A SIOPEN Biology Study
2026
·
Alexandra Saint-Charles
, Julien Masliah-Planchon
, et al.
·
Newcastle University ePrints (Newcastle Univesity)
Harmonization of Reporting of ALK Genetic Alterations in Neuroblastoma
2025
·
Alexandra Saint-Charles
, Julien Masliah-Planchon
, et al.
·
Journal of Molecular Diagnostics
Supplementary information from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure S2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure S1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure S4 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Supplementary data 1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Supplementary data 3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Supplementary data 2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure S3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Data from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure 6 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure 5 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Table 1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Supplementary data 2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure S2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure 4 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure 1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure S4 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Show more works
View as search
Works count:
40
Citation count:
29
H-index:
3
I10-index:
1
Year
Topic
Type